| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
|
J Clin Oncol
|
2013
|
1.96
|
|
2
|
Breast cancer subtypes and survival in patients with brain metastases.
|
Breast Cancer Res
|
2008
|
1.95
|
|
3
|
Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
|
Breast Cancer Res Treat
|
2009
|
1.45
|
|
4
|
Web-based tailored education program for disease-free cancer survivors with cancer-related fatigue: a randomized controlled trial.
|
J Clin Oncol
|
2012
|
1.34
|
|
5
|
Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.30
|
|
6
|
Validation study of the korean version of the brief fatigue inventory.
|
J Pain Symptom Manage
|
2005
|
1.18
|
|
7
|
The attitudes of cancer patients and their families toward the disclosure of terminal illness.
|
J Clin Oncol
|
2004
|
1.15
|
|
8
|
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
|
Cancer Chemother Pharmacol
|
2011
|
1.13
|
|
9
|
Metaplastic breast cancer: clinicopathological features and its prognosis.
|
J Clin Pathol
|
2012
|
1.13
|
|
10
|
Validation study of the Korean version of the M. D. Anderson Symptom Inventory.
|
J Pain Symptom Manage
|
2006
|
1.12
|
|
11
|
Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study.
|
Breast Cancer Res
|
2011
|
1.08
|
|
12
|
Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.05
|
|
13
|
Health-related quality of life in survivors with breast cancer 1 year after diagnosis compared with the general population: a prospective cohort study.
|
Ann Surg
|
2011
|
1.04
|
|
14
|
Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer.
|
Clin Chem
|
2006
|
1.04
|
|
15
|
Chylothorax in Gorham's disease.
|
J Korean Med Sci
|
2002
|
1.03
|
|
16
|
Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
|
Ann Surg Oncol
|
2009
|
0.99
|
|
17
|
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
|
Breast Cancer Res Treat
|
2008
|
0.98
|
|
18
|
High volumetric breast density predicts risk for breast cancer in postmenopausal, but not premenopausal, Korean Women.
|
Ann Surg Oncol
|
2014
|
0.97
|
|
19
|
Assessment of clinical relevant fatigue level in cancer.
|
Support Care Cancer
|
2007
|
0.97
|
|
20
|
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.96
|
|
21
|
Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case-control study.
|
BMC Cancer
|
2009
|
0.96
|
|
22
|
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
|
Breast Cancer Res Treat
|
2010
|
0.92
|
|
23
|
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
|
Breast Cancer Res Treat
|
2011
|
0.90
|
|
24
|
Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.89
|
|
25
|
Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases.
|
BMC Cancer
|
2009
|
0.88
|
|
26
|
Use of a decision aid to help caregivers discuss terminal disease status with a family member with cancer: a randomized controlled trial.
|
J Clin Oncol
|
2011
|
0.88
|
|
27
|
Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to St Gallen consensus and intrinsic subtypes.
|
J Surg Oncol
|
2010
|
0.87
|
|
28
|
Phase 2 trial of accelerated, hypofractionated whole-breast irradiation of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions in early-stage breast cancer.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.86
|
|
29
|
Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.
|
Breast Cancer Res Treat
|
2014
|
0.85
|
|
30
|
Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer.
|
Cancer Res Treat
|
2006
|
0.85
|
|
31
|
The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
|
BMC Cancer
|
2010
|
0.84
|
|
32
|
Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast.
|
Invest New Drugs
|
2008
|
0.84
|
|
33
|
Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer.
|
Oncol Rep
|
2008
|
0.84
|
|
34
|
Factors influencing preferences for place of terminal care and of death among cancer patients and their families in Korea.
|
Support Care Cancer
|
2005
|
0.84
|
|
35
|
Hypomethylation of the interleukin-10 gene in breast cancer tissues.
|
Breast
|
2010
|
0.84
|
|
36
|
Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
|
J Clin Oncol
|
2010
|
0.84
|
|
37
|
Comparison of sentinel lymph node biopsy guided by the multimodal method of indocyanine green fluorescence, radioisotope, and blue dye versus the radioisotope method in breast cancer: a randomized controlled trial.
|
Ann Surg Oncol
|
2013
|
0.83
|
|
38
|
Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues.
|
J Mol Med (Berl)
|
2010
|
0.83
|
|
39
|
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
|
Breast Cancer Res Treat
|
2015
|
0.82
|
|
40
|
Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer.
|
Tumour Biol
|
2014
|
0.82
|
|
41
|
A case of locally advanced breast cancer complicated by pulmonary tumor thrombotic microangiopathy.
|
Cancer Res Treat
|
2012
|
0.82
|
|
42
|
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
|
Invest New Drugs
|
2011
|
0.81
|
|
43
|
Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in korean women with locally advanced breast cancer.
|
J Breast Cancer
|
2011
|
0.81
|
|
44
|
Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients.
|
Asian Pac J Cancer Prev
|
2012
|
0.80
|
|
45
|
Percutaneous radiofrequency ablation for liver metastases in breast cancer patients.
|
Breast J
|
2013
|
0.78
|
|
46
|
Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
|
Invest New Drugs
|
2009
|
0.78
|
|
47
|
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
|
Breast Cancer Res Treat
|
2011
|
0.78
|
|
48
|
Factors associated with place of death in koprean patients with terminal cancer.
|
Asian Pac J Cancer Prev
|
2013
|
0.77
|
|
49
|
High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization.
|
Korean J Intern Med
|
2005
|
0.77
|
|
50
|
A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer.
|
Lung Cancer
|
2006
|
0.77
|
|
51
|
Social support and depressive mood 1 year after diagnosis of breast cancer compared with the general female population: a prospective cohort study.
|
Support Care Cancer
|
2010
|
0.76
|
|
52
|
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
|
PLoS One
|
2012
|
0.76
|
|
53
|
Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
|
Dis Colon Rectum
|
2009
|
0.76
|
|
54
|
Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
|
Oncol Rep
|
2009
|
0.75
|
|
55
|
A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
56
|
A case of primary gastric CD30-positive anaplastic large-cell lymphoma.
|
J Korean Med Sci
|
2005
|
0.75
|
|
57
|
Stage-to-stage comparison of neoadjuvant chemotherapy versus adjuvant chemotherapy in pathological lymph node positive breast cancer patients.
|
Jpn J Clin Oncol
|
2012
|
0.75
|
|
58
|
A Phase II Study of Ifosfamide, Carboplatin, and Epirubicin (ICE) Combination Chemotherapy for Extensive Disease of Small Cell Lung Cancer.
|
Cancer Res Treat
|
2002
|
0.75
|
|
59
|
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
|
Invest New Drugs
|
2010
|
0.75
|
|
60
|
A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
|
61
|
Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea.
|
Oncology
|
2016
|
0.75
|